Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SER-401 + Nivolumab in Advanced Melanoma
NCT03817125Phase 1Completed
- Sponsor
- Parker Institute for Cancer Immunotherapy
- Start
- Jan 2019
- Primary completion
- Mar 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in melanoma comparing SER-401/ Nivolumab with Placebo/ Nivolumab (2 arms). Primary endpoint: Percentage of Patients With Adverse Events at 2 years. Started Jan 2019; status: completed.
02
Drugs
SER-401
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03817125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817125.